The neurogenic potential of astrocytes : a story of transformation and renewal by Santopolo, Giuseppe
Thesis for doctoral degree (Ph.D.)
2020
The Neurogenic Potential of Astrocytes: 





















eurogenic Potential of A
strocytes: A
 Story of Transform
ation and Renew
al
From Department of Cell and Molecular Biology 
Karolinska Institutet, Stockholm, Sweden 
THE NEUROGENIC POTENTIAL OF 
ASTROCYTES: A STORY OF 





All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by US-AB 
© Giuseppe Santopolo, 2020 
ISBN 978-91-7831-939-8 
On the cover: Representation of the transformation process that leads from astrocytes to 
neurons. Watercolor by Alexandra Cîrciumaru.
The Neurogenic Potential of Astrocytes: a Story of 
Transformation and Renewal 



























University of Gothenburg 

















To my family. 
 
“Above all, don’t fear difficult moments. The best comes from them.” 







To not simply repair an organ, but to regenerate and fully recover its function, like there was 
no injury at all, that is the goal of regenerative medicine. Of all the organs in the human body, 
the most delicate and difficult to regenerate is the human brain. Our understanding of its 
physiology changed dramatically in the last decades and the concept of the human brain as a 
never-changing tissue, where neurons are lost, but not produced after development is no 
longer valid. Today we know that new neurons constantly form and re-shape the connections 
between each other and that even in the adult brain, there are populations of stem cells that 
generate new neurons. Nevertheless, after an injury, a recovery ad initio is not possible in the 
adult human brain. 
Different approaches have been tried to change this inability of the brain to regenerate. Stem 
cells have been the main target for the majority of these strategies, either by stimulating stem 
cells, which reside in the brain, or by retrieving them from outside sources. The problem with 
the endogenous stem cells is that, in the adult brain, they are not very active and can generate 
a very limited number of new neurons, which are insufficient for the recovery of the damaged 
tissue. As for the external sources of stem cells, these are not always available and they may 
involve problems of graft rejection. Therefore this is the reason for looking at alternative 
options within the brain itself. 
Astrocytes are one of the most represented cell types in the adult mammalian brain, they can 
be easily generated and are strikingly similar to the stem cells. Astrocytes have been observed 
to generate neurons in animal models of Huntington’s disease and stroke. Notch signaling 
seems to be crucial in regulating the neurogenic ability of astrocytes. In animal models where 
Notch signaling is impaired by deletion of Rbpj, astrocyte-derived neurons and neurogenic 
cells can be identified within the striatum. But many questions are still open: what processes 
are necessary for the astrocytes to generate neurons? Why do astrocytes from the striatum 
generate neurons, while astrocytes in other brain regions do not? Can we harness this 
neurogenic potential and use it in regenerative medicine? If so, how? These are some of the 
questions I tried to answer with my work. 
 
In Paper I, we combined the two models we have previously described to induce astrocyte-
derived neurogenesis. We blocked Notch signaling specifically in astrocytes by using an 
animal model in which Rbpj is knocked-out in Cx30-expressing cells. Subsequently, we 
induced a stroke in the same animals. After seven weeks, we observed an increase in the 
number of neuroblasts derived from astrocytes, compared to the deletion of Rbpj or stroke 
alone. This study shows that astrocyte-derived neurogenesis is a complex process, which can 
be induced by different kinds of stimuli, and further enhanced by their interplay. 
 
In Paper II, we decided to further investigate what happens in astrocytes, on a transcriptomic 
level, when they become neurogenic. We used single-cell RNA sequencing to identify the 
differences between neurogenic and non-neurognic astrocytes at different time-points. We 
observed that, during differentiation into neurons, striatal astrocytes follow a trajectory that is 
reminiscent of the one followed by stem cells of the subventricular zone. Moreover, they start 
to sense the environment for pro-neurogenic factors. One of this is Egf, which administration 
in the brain of Rbpj-deleted mice enhances astrocytes-derived neurogenesis. Remarkably, the 
effect of Egf is visible even in areas of the striatum where astrocytes do not respond in the 
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The greatest challenge of regenerative medicine is to understand which mechanisms are 
crucial not only to control the damage after an injury occurs, but also to reconstruct a tissue 
with its full functionality. Physiologically, adult mammals lack the ability to fully regenerate 
tissues after injury (with few exceptions such as the liver from a functional point of view) and 
this is particularly accentuated in humans. Our understanding of the regenerative process 
changed dramatically in the last decades. Today we know that the regenerative ability of 
specific tissues directly correlates with the presence of specialized cells able to proliferate and 
differentiate into tissue specific cell types. This role is usually undertaken by stem and 
progenitor cells. Tissues where stem cells are limited in number or in their ability to 
proliferate and differentiate regenerate poorly. The brain is one of the most striking examples. 
Even if stem cells within the brain keep generating new neurons throughout adulthood as 
reported in early works in the field (1–3), their ability to respond to an injury is limited. In 
humans neuronal death with loss of functionality following injury is often permanent. 
Efforts have been made to enhance the regenerative ability of the stem cells in the adult brain, 
albeit with little success. New approaches aimed at finding different sources of new neurons, 
within the brain itself or from exogenous sources showed more promising results. Our work 
focused on a cell type that was initially overlooked in its ability to generate neurons, but 
holds a great potential: astrocytes. Although counterintuitive at first glance since astrocytes 
are involved in the formation of scar tissue after acute lesions such as stroke or traumatic 
injuries, their high numbers and spread distribution within the brain along with their 
resemblance to stem cells makes them an interesting resource of neuron generation. A 
neurogenic potential of astrocytes has already been described in the past years. Astrocytes 
can generate immature and mature neurons in artificial settings, such as when isolated from 
the rodent brain (4) or through in vivo reprogramming techniques (5–7) and also as a 
physiological response to injury in the mouse striatum (8,9). 
The aim of this thesis is to characterize the mechanisms that regulate the neurogenic program 
in astrocytes. We developed tools that could be used in the identification of important factors 
to improve astrocyte-derived neurogenesis. We also proved that, by providing appropriate 







2 NEURAL STEM CELLS AND NEUROGENESIS 
 
To fully understand the concept of regenerative medicine, we need to understand how 
different cell types can be generated in the adult brain. Tissue regeneration is virtually a 
ubiquitous process, occurring even in the brain and often carried out by stem cells, but very 
limited in mammals when compared to other animals like fishes and amphibians. Until the 
1960s it was believed that neurogenesis, the phenomenon by which new neurons are formed, 
occurred only during embryonic development. Once the developmental phase was over 
neurons could die and never be generated anew. Our understanding of the brain changed with 
the discovery that new neurons are actually formed in the brain of adult mammals (1) by cells 
with stem cell properties named Neural Stem Cells (NSCs) (2,3,10). 
Time, place and numbers of newly generated neurons greatly differ between species (11). In 
the case of rodents, by far the most common animal model for the study of neurogenesis, 
NSCs are found in two canonical niches: a region lining the Lateral Ventricle (LV) called 
Subventricular Zone (SVZ) and the Dentate Gyrus (DG) of the hippocampus. Under 
physiological conditions, NSCs from these two niches generate new neurons following a 
well-characterized pathway that will be further discussed in this chapter.  
 
2.1 NEUROGENESIS AND NEUROGENIC NICHES IN RODENTS 
2.1.1 The subventricular zone 
One of the main neurogenic niches in the mammalian brain is the SVZ, which is an area 
adjacent to the LV. Within the SVZ reside different cell types, including ependymal cells, 
astrocytes and the NSCs (Figure 1). The precursor cells from the SVZ have been classified 
into three categories: type B, C and A. The type B cells, the proper NSC, are identified by the 
expression of markers such as Glial fibrillary acid protein (Gfap), Nestin and Sox2. Just as 
their embryonic equivalents, they retain the basic apical-basal polarity and the ability of self-
renewal and multipotency (12). Type C cells can be recognized by the expression of the 
markers Sox2, Dlx and Olig2. They are also called transit-amplifying progenitor cells. They 
represent an intermediate stage where NSCs activate and undergo several cycles of 
proliferation into a short period and then terminally differentiate. Type A cells are the 
migrating neuroblasts expressing Doublecortin (Dcx) and polysialylated-neural cell adhesion 
molecule (Psa-Ncam). Neuroblasts are immature neurons that towards the end of their 
differentiation process start to express Tuj1, a typical marker for mature neurons. Chains of 
migrating neuroblasts trek through the Rostral Migratory Stream (RMS) from the SVZ to 
reach the Olfactory Bulbs (OB). Here the neuroblasts detach from the chains of migrating 
cells, disperse within the OB and differentiate into granule and periglomerular neurons 
(13,14). It is important to note that the nature of the newly generated neuron depends on the 
origin of the NSCs: deep granule cells and calbindin-expressing periglomerular cells are 
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generated by NSCs located in the ventral part of the SVZ, whereas superficial granule cells 
and tyrosine-hydroxylase-expressing periglomerular cells are produced by NSCs from the 
dorsal SVZ (15). It is still under debate whether this difference in neurogenic potential is 
intrinsic to the original NSCs or rather dictated by environmental factors. 
Like all stem cell populations, NSCs have the ability to self-renew and give rise to 
differentiated cell types. Initially NSCs were thought to be tri-potent, meaning they could 
generate neurons, astrocytes and oligodendrocytes. This hypothesis came from in vitro 
experiments which demonstrated the development of these cell types in neurosphere assays of 
monolayer cell cultures (10,16). Further studies based on population fate-mapping of NSCs 
from the SVZ revealed however that only neurons and oligodendrocytes can be generated 
(17) and even more recent in vivo clonal analysis has proven that NSCs from the SVZ 
generate solely neurons (18). Nevertheless, in vitro individual NSCs have the ability to 
generate either neurons or oligodendroglial cells but never both cell types (19). Whether 
NSCs from the adult mammalian brain have a tri-lineage potential remains a topic that 
requires further investigation. Some groups proposed that NSCs become specific gradually 
during development and lose their ability to generate multiple cell types in the adult brain 
(20). Another model suggests that adult NSCs could be intrinsically tri-potent, but the niche 
is suppressing their ability to generate specific cell types. The ability of endogenous adult 
NSCs to self-renew in the long-term is also under debate. Studies involving clonal analysis 
revealed that, following a phase of expansion, there is a depletion of NSCs (18). Genetic 
labeling approaches do not come to help in this context, since each model may target 
different sub-populations of NSCs or the same sub-population at different states, producing 
inconsistent/discordant/inconclusive results. Understanding the extent to which NSCs have 
self-renewal capacity will be a critical challenge for the future, with the promise of 
developing better targeting approaches. 
The NSCs have a specialized apical process with a primary cilium, reminiscent of radial glial 
cells, that allows the NSCs to be in direct contact with the LV. The apical endings of the 
NSCs are surrounded by ependymal cells, which are necessary for the formation of 
intercellular junctions between NSCs and ependymal cells within the niche (21). Another role 
of the ependymal cells is to maintain the molecular composition of the stem cell niche by 
allowing the cerebrospinal fluid to (re)circulate (22). The cerebrospinal fluid is able to 
modulate the NSCs behavior because it is rich in soluble factors such as Insulin-like growth 
factor 2 (Igf2) (23), Bone morphogenic proteins (Bmps) (24,25), secreted Wingless (Wnt), 
Sonic hedgehog (Shh) and retinoic acid (26,27). 
The Notch/Delta signaling maintains NSCs in an undifferentiated status by inhibiting the 
production of transit-amplifying progenitor cells (28). Type C cells express high levels of 
Achaete-scute homolog 1 (Ascl1), which is repressed by Hairy and enhancer of split-1 
(Hes1), one of Notch’s target genes. Ascl1 promotes Notch ligands expression, suggesting 




The neurogenic environment in the SVZ is further improved by the local characteristics of the 
Blood Brain Barrier (BBB) that is more permeable around the SVZ, allowing some Growth 
Factors (GF) to diffuse (31). Furthermore, on the basal end of the NSCs, there are processes 
that come in direct contact with the blood vessels. This facilitates the flow of vascular factors 
which are potentially stimulating neurogenesis in the SVZ. Indeed, infusion of Vascular 
endothelial growth factor (Vegf) promote cell proliferation in the SVZ (32). Epidermal 
growth factor (Egf) and Fibroblast growth factor 2 (Fgf2) maintain pools of NSCs both in 
vitro and in vivo. However, only Fgf2 increases the number of newly generated neurons (33). 
Egf has been reported to inhibit the differentiation of transit-amplifying progenitor cells into 
neuroblasts (34). Interestingly, by inducing the expression of the receptor tyrosine-protein 
kinase ErbB2, Gfap expressing cells in the adult SVZ re-acquire radial glia morphology. This 
would suggest that Egf has a role in the inhibition of NSCs differentiation (35). 
Until here I discussed the role of the major canonical signaling pathways in regulating adult 
neurogenesis along with other intracellular mechanisms known to affect this process. Several 
transcription factors play a crucial role in adult neurogenesis. The orphan nuclear receptor Tlx 
and Bmi-1 are required for the maintenance of adult forebrain NSCs (36). Pax6 induces 
differentiation of progenitor cells from the SVZ into neurons (37), while Olig2 has an 
opposite effect (38,39).  
Epigenetic modifications are also involved in regulating adult neurogenesis: increased 
genomic instability is observed in NSCs that lack the Methyl-CpG binding protein 1 (Mbd1), 
resulting in decreased neuronal differentiation.  
  
Figure 1: Location of the SVZ in the LV and magnification to illustrate the structure of the neurogenic niche. 
Type B cells are surrounded by the ependymal cells (E), forming pinwheel-like structures on the ventricular 
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surface. Type B (NSCs) cells differentiate into type C cells (the transit-amplifying progenitor cells), which 
divide to generate type A cells, also known as neuroblasts. The NSCs cells retain a process on the apical side 
containing a cilium responsible to contact the lateral ventricle. On the basal side, instead, there is a long 
process ending on blood vessels (BV in the figure). (Image from Fuentealba LC, Obernier K, Alvarez-Buylla 
A. Adult neural stem cells bridge their niche. Cell Stem Cell. 2012;10(6):698-708. 
doi:10.1016/j.stem.2012.05.012. Used with permission from Cell Press). 
 
2.1.2 The dentate gyrus of the hippocampus 
The second main neurogenic niche in the mammalian brain is the DG (Figure 2). Here, the 
NSCs are also called type-1 progenitors and they present radial glia-like features. In the DG, 
NSCs extend an apical process through the granular cell layer. As in the SVZ, NSCs express 
Gfap, but also vimentin, and Brain lipid-binding protein (Blbp), common to immature 
astrocytes and radial glia. Until recently the common understanding was that in normal 
conditions only 1-2% of the NSCs in the hippocampus undergo active division (40–42), thus 
the NSCs from the DG were considered quiescent cells. New studies involving single-cell 
transcriptome analysis of quiescent adult NSCs from the DG showed expression of receptors 
involved in niche signals and downstream signaling components. Once NSCs become active, 
many of these signals are down-regulated (43). In particular, decreased levels of GABA (44) 
or Wnt inhibitor (45) leads to activation of the NSCs. Therefore, quiescence needs to be 
actively maintained. The idea that stem cells are active as long as the environment does not 
suppress their replication is becoming more and more established within the scientific 
community even for other stem cell types and the topic has been reviewed elsewhere (46). 
Other important signaling pathways involved in the regulation of equilibrium between 
quiescence and the entrance in cell cycle are the Bmp. The NSCs in the DG express the Bmp-
receptor 1A. When activated by its ligands Bmp-2 and Bmp-4, Bmp-receptor 1A start a 
cascade that enables the maintenance of the quiescence of the NSCs (47). On the other hand, 
Noggin can bind the Bmp, inducing the NSCs activation and entry into the cell cycle. In 
addition, Shh and canonical Notch signaling are also responsible for the quiescence and 
activation of the NSCs in the DG (48,49). Sox1 plays an important role in NSC activation: 
Sox1 positive NSCs in the DG produce precursors that can further differentiate into neurons 
and astrocytes (50).  
NSCs in the DG divide by asymmetric divisions to generate transit amplifying progenitor 
cells that in the DG are also called type-2 cells. As in the SVZ, these cells proliferate more 
intensively than the type-1 and are able to differentiate into the type-3, the neuroblasts. The 
majority of the neuroblasts is not needed and undergoes apoptosis (51,52). The surviving 
cells differentiate into mature neurons. Interestingly, the existence of a second population of 
hippocampal NSCs had been proposed (49). These cells do not present the standard radial 
structure and are called horizontal hippocampal stem cells. Nevertheless, further 
characterization of this type of cells is still to be done.  
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The process described above requires several weeks and once completed newly generated 
neurons are integrated in the DG. These neurons are hyper-excitable and exhibit a lower 
threshold for induction of long-term potentiation compared to mature neurons, resembling 
their developmental counterparts (53). Adult-born neurons also induce plasticity, by creating 
new synaptic connections with the pre-existing neurons. These features contribute to create 
variability in the information coding within the brain circuits. 
By this point one question remains unanswered: what could be the function of these newly 
generated neurons? New neurons, both in the hippocampus and in the OB seem to be critical 
for the process of new memory formation (54–56). In particular, neurogenesis in the DG 
contributes to long-term spatial memory and pattern separation (57–59). In the OB, 
interneurons are involved in short-term olfactory memory and olfactory associative learning 
(60).  
 
Figure 2: Location of the DG in the hippocampus and magnification of the stem cell niche. Type-1 cells are 
the radial glia like cells (RA). Tyoe-2 are the intermediate progenitors (IPC 1 and 2 in the figure) that can 
differentiate into type-3 cells, the neuroblasts (IGC). Finally, the type-3 cells will migrate and differentiate 
mature granule cells (GC in the figure). (Image from Fuentealba LC, Obernier K, Alvarez-Buylla A. Adult 
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neural stem cells bridge their niche. Cell Stem Cell. 2012;10(6):698-708. doi:10.1016/j.stem.2012.05.012. 
Used with permission from Cell Press). 
 
2.1.3 Neurogenesis outside the canonical niches 
Throughout the years neurogenesis has been described in other brain regions than the SVZ 
and the DG, but, since these areas are not conserved between species or experience 
neurogenesis only as a response to injury, they are not considered canonical niches. 
In different rodent species, pigs and primates the following areas have been observed to 
harbor neuroblasts: the striatum, neocortex, amygdala, piriform cortex and adjoining 
perirhinal cortex (61,62). In rabbits, which on the evolutionary scale are as distant from 
humans as mice, striatal neurogenesis has been observed in physiological conditions (63). 
Similar observations have been done in rats (64,65) and non-human primates (66), although 
these results have not been replicated in other studies and require caution (67,68). Under 
physiological conditions, neurogenic cells are never observed very far from the SVZ. This 
may be because the niche plays a critical role in the creation of a pro-neurogenic 
microenvironment.  
Putting together all the information listed until now, it is clear that our understanding of adult 
neurogenesis in mammals walked a long way since the 1960s. But one question arises when 
reading what is known about rodents: what do we know about the adult human brain? 
 
2.2 ADULT NEUROGENESIS IN THE HUMAN BRAIN 
The first part of this thesis discussed the topic of adult neurogenesis in the mammalian brain 
and the animal models; rodents in particular, have been considered the paradigm for it. 
Nevertheless, the interest of the scientific community and of society is aimed at 
understanding how much of this knowledge applies to humans. In many ways, humans are 
very different from the rodents and the brain in particular has many layers of complexity that 
the rodent brain cannot represent. That is why much effort is aimed at understanding if and 
how neurogenesis occurs in the adult human brain. 
 
2.2.1 Neurogenesis in the human subventricular zone and striatum 
To assess the neurogenic potential of the human brain the first step is the identification of the 
NSCs and the stem cells niches (or their equivalents). The natural places to start are the LV 
and the hippocampus (Figure 3). A meticulous investigation of the human LV and SVZ 
identified the presence of a ribbon of GFAP-expressing astrocytes, but lacked the chain 
migration of neuroblasts typical of mouse SVZ (69). A later study also revealed, within the 
human SVZ the presence of PSA-NCAM positive cells, a typical marker for neuroblasts, but 
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failed to identify DCX expressing cell (70). It is important to mention at this point that the 
presence of specific cellular markers widely used in rodents are not as reliable when 
characterizing the human brain. Due to some differences in expression patterns and technical 
difficulties in the tissue processing, the presence or absence of markers like DCX or PSA-
NCAM should not be used as a definitive proof. An example is given by the marker DCX 
which is not restricted to neuroblasts in the human brain (71). More about this topic will be 
discussed later. 
To understand if some of these differences are due to incomparable neurogenic mechanisms 
between rodents and humans, studies of the infant and fetal human brain have been 
conducted. Both the fetal and post-natal human forebrains have been found to be populated 
by high numbers of cells that are actively proliferating and expressing neurogenic markers 
such as DCX and PSA-NCAM (72), and vimentin (73). Moreover, although some 
neuroblasts in the fetal and post-natal human brains do form chains of migrating cells seen 
instead in the rodent and the primate brains, most neuroblasts migrate tangentially to the LV. 
Some of the neuroblasts that migrate in chains have also been observed to detach from the 
RMS and trek towards the prefrontal cortex, leading to speculation regarding the role of these 
neuroblasts in the human brain compared to the rodents and the target regions of adult human 
neurogenesis. Neurogenesis from the SVZ in humans seems to decline very rapidly and 
become almost undetectable 9 months after birth (73). After this initial finding, later studies 
questioned the existence of the RMS in humans with contrasting results. Proliferative cells 
have been reported surrounding an extension of the SVZ towards the OB (74), but later 
studies, that confirmed the existence of the described structure, could not identify the 
proliferating and migrating neuroblasts (72,73). Nevertheless, such differences in results may 
be due to the panel of markers chosen to assess proliferation.  
As previously discussed, SVZ derived neurogenesis in rodents is a mechanism, which ensures 
the formation of new neurons that will integrate into the pre-existing circuits of the OB. This 
is not the case for humans and this may be easily explained by the fact that olfactory 
perception in our species does not play such an important role as for rodents. 
Quantification of neurogenesis in humans has also been a challenge in the field. Considering 
the rarity and ambiguity of NSCs in the human SVZ and the difficulty in tracing neuroblasts 
and newly generated neurons, studies based on staining were not capable of estimating the 
number of neurons that are generated in the adult human brain. The application of techniques 
based on the analysis of the 14C levels in the neuronal population provided an answer to this 
question. The rationale behind this technique is that 14C concentration in the human body 
closely mirrors the atmospheric levels (75–77). Due to the aboveground tests for nuclear 
weapons during the 1950s and ‘60s, the levels of 14C in the atmosphere almost doubled, to 
then slowly go back towards pre-tests levels after the Test Ban Treaty of 1963. These changes 
in the levels of atmospheric 14C concentration have been used to date the age of cells. When a 
cell will undergo mitosis, 14C will be integrated into the newly synthetized DNA. The 
concentration of 14C in the DNA, will therefore mirror the concentration in the atmosphere at 
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that precise moment (78–81). When such technique was used to estimate the neuronal 
turnover in the human OB the 14C concentration in the DNA was not different from the 
concentration at the time of birth and mathematical modeling of the results estimated that no 
more than 1% of the neurons from the OB could have been replaced during adulthood 82. 
Taken together, this points out that adult neurogenesis in the human SVZ is not aimed at 
replacing neurons in the OB. 
Given that NSCs in the human SVZ differentiate into neuroblasts and that these neuroblasts 
do not seem to generate neurons destined for the OB or undergo apoptosis (83), one could 
wonder as to where are the new neurons generated in the human brain? The observations in 
the OB where not surprising after all since, as mentioned, the OB in humans are less 
complex/sensitive than the rodents’. However, there is another area in the human brain that 
would instead experience an increase in complexity compared to rodents and that is localized 
close to the SVZ: the striatum. The analysis of iododeoxyuridine (IdU) incorporation in the 
brain of patients treated for cancer revealed IdU positive interneurons in the striatum (83). 
This meant that these interneurons must have been generated during adulthood, when the 
patients were treated with IdU. In the same study, 14C concentration in the neuronal 
population from the striatum revealed that only DARP23 negative interneurons are generated, 
with a turnover of approximately 2.7%/year according to the most likely mathematical model 
(83). Although no formal demonstration is given of the SVZ origin of these adult-generated 
interneurons, considering the distance from the SVZ and the presence of NSCs and 
neuroblasts that migrate tangentially from the LV, it is interesting to speculate if, during the 
evolution of the human brain, the increasing complexity of the striatum compared to the OB 
and the need for new neurons to be generated induced a change in the final destination of the 
SVZ-derived neuroblasts. Later studies failed to replicate such results and instead suggest that 
there is no neurogenesis in the human striatum (68) and more research is needed to get a 
definitive answer. 
 
2.2.2 Neurogenesis in the human hippocampus 
The second neurogenic niche common in mammals is the hippocampus, which in recent 
years attracted interest, due to contrasting results and the re-evaluation of the topic using new 
techniques. As already shown for the SVZ, the first approach to verify the existence of NSCs 
and neurogenesis in the human hippocampus was based on quantification of 
bromodeoxyuridine (BrdU) positive neurons in the brains from patients treated for cancer. As 
for IdU quantification in the striatum, BrdU is incorporated in the DNA during cell division. 
The presence of BrdU in the neurons of the patients could mean that these neurons derive 
from NSCs that underwent division while the patient was under treatment (84). 
Later studies aimed at validating the information accumulated about murine hippocampal 
neurogenesis in humans. Cells positive for DCX were identified in the DG dissected from 
individuals of age ranging from 1 to 100 years (85). These cells not only expressed DCX, but 
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also a panel of markers associated with hippocampal neurogenesis in mice, such as the 
proliferation markers Ki67 and Mem2, the transcription factor Prox1 (associated with granule 
cell development) and the calcium binding protein calretinin. For older individuals, DCX 
expressing cells were often found to be positive for the neuronal marker NeuN, information 
that today has to be considered more carefully, considering the concerns regarding DCX 
expression in humans (discussed in (86)). As observed for the SVZ, it was clear that the DG 
suffers a decline in neurogenesis within the first years after birth (85). 
Analysis of the 14C concentration in the human hippocampus confirmed that both the non-
neuronal and neuronal populations experience turnover throughout life. In particular, it seems 
that two populations of neurons constitute the human hippocampus: one with a turnover rate 
of approximately 1.75% per year, while the second is not renewed at all (87). By using this 
method, it was also possible to model the decline in hippocampal neurons and verify that it 
closely resembles the decline described in neuroblasts. 
Recently, the debate on human neurogenesis in the adult DG was re-ignited by contrasting 
results regarding the presence of DCX positive cells in the adult human hippocampus (88,89). 
The scientific community now questions the use of DCX and PSA-NCAM as markers for 
neurogenesis in humans, as it seems that these markers can easily degrade and become 
difficult to stain if the post-mortem interval is prolonged (86,90). Moreover, independently of 
the presence of DCX and PSA-NCAM positive cells, the results obtained with BrdU and 14C 
quantification are not disproven.  
Many questions remain unanswered on what is the role of neurogenesis in the adult human 
brain, its potential in regenerative medicine and to which extent we can control it in order to 
develop new therapies. More about this will be discussed in the next chapter. 
 
Figure 3: Comparison of the neurogenic niches between mouse and human. A) Location of the LV and DG in 
the mouse brain. B) Location of LV, striatum and DG in the human brain (Image from Magnusson JP, Frisén J. 
Stars from the darkest night: unlocking the neurogenic potential of astrocytes in different brain 
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3 REGENERATIVE MEDICINE OF THE BRAIN 
 
The discovery of adult NSCs and their ability to generate new neurons raised hopes that they 
could be involved in tissue repair following injury. However, apart from conferring an 
additional layer of plasticity to the brain, it seems that NSCs in the adult mammalian brain are 
not adapted to efficiently regenerate large portions of tissue. Nevertheless, as discussed in this 
chapter, NSCs respond to different kind of injuries and neurodegenerative disease. 
Understanding which mechanisms are involved in the neurogenic response and what are the 
factors playing against it brings the possibility of manipulation in the view of improving the 
regenerative capacity of the human brain. In this chapter I will discuss the neurogenic 
response to some types of injuries and diseases, with a particular focus on stroke. In the 
second part, I will summarize the approaches that have been taken until now to enhance the 
neurogenic response to damage. 
 
3.1 REGENERATIVE RESPONSE TO INJURY 
An endogenous neurogenic response has been observed following injury during 
neurodegenerative diseases. Quantifications of Ki67 expression or BrdU incorporation have 
proven that NSCs undergo proliferation following seizure activity in the rodent DG and SVZ 
(91–94). This seems to be triggered by the ability of NSCs to sense the electrical activity 
around them (59), by activation of their GABA receptors (44,95,96) or epigenetic changes 
induced by seizure (97,98). The increase in number of proliferating cells after seizures is 
mirrored by an increased number of new neurons, as assessed by the expression of neuronal 
markers in BrdU positive cells 4 weeks after seizure (91,93). Many of these new neurons 
show signs of abnormalities, that can potentially alter the connectivity within the 
hippocampus (99–101). In the SVZ, the seizure-induced neurons migrate more rapidly than in 
normal conditions, often leaving the RMS prematurely (94). 
Neurogenesis and the neurogenic niches are also affected in different neurodegenerative 
diseases, but in different ways depending on the disease. From post-mortem brain analysis, 
researchers described increased cell proliferation in the DG of patients affected by Alzheimer 
disease (AD) and in the SVZ of patients with Huntington’s disease (HD), but neurogenesis 
was decreased in the DG and SVZ of patients with Parkinson’s disease (PD), as discussed in 
the rest of this chapter.  
Neurogenesis in AD is a controversial topic, while some early studies found that markers for 
neurogenesis and for neuronal cell types are overexpressed in the human DG (102), 
suggesting that new neurons are formed, more recent studies observed a steep decrease in 
neurogenesis in AD brain (103,104). Many animal models have been generated to study how 
neurogenesis is affected in the AD brain, but the results are conflicting. Some studies 
reported that mice carrying mutations in the presenilins-1 gene had reduced proliferation in 
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the hippocampus and only the wild-type human presenilin-1 gene overexpression promoted 
survival and differentiation of NSCs into immature neurons (105,106). Nevertheless, 
different mutations of presenilin-1 have instead been associated with enhanced proliferation 
and neurogenesis in the mouse brain (107). Regardless of whether these mutations induce an 
increase or a decrease in hippocampal neurogenesis, it seems clear that presenilin-1 mutations 
affect the neurogenic process in the adult hippocampus, and this may have a significant 
contribution in the pathogenesis of AD. 
Similar inconsistencies in results have been observed in other mouse models for AD: 
mutations of the gene encoding amyloid precursor protein have been associated with both 
decreased (108–110) and increased (111) proliferation and neuronal survival. 
Other neurodegenerative diseases have been modeled in animals by overexpressing the wild 
type or mutated form of α-synuclein that accumulates in PD, dementia with Lewy bodies and 
multiple system atrophy. Overexpression of the wild-type protein is associated with 
decreased neuronal survival in both the DG and SVZ. While expression of wild-type α-
synuclein does not affect the NSCs proliferation rate, mutations of this protein are associated 
with decrease proliferation in the SVZ (112). 
All the injury models presented so far affect the neurogenic process and cause a loss of 
neurons. Many more could be included in this list, i.e. inflammation and cancer, however 
our focus resides in one particular model: stroke. 
 
3.2 STROKE: DISEASE AND NEUROGENIC RESPONSE TO INJURY 
3.2.1 Ischemic stroke 
Stroke is one of the most common neurological diseases in the western world and 13.7 
million people experience a stroke every year. Stroke is fatal in almost half of the cases and it 
has debilitating outcomes for 5.5 millions people every year (113). There are three types of 
stroke: hemorrhagic stroke, in which a blood vessel rupture causes bleeding in the brain; 
transient ischemic stroke, a temporary blockage or reduce in the blood flow, that usually does 
not have a longstanding effect; and ischemic stroke, when a blood vessel is occluded. The 
latter is the most common form of stroke, accounting for approximately 87% of all cases. The 
ischemic stroke is characterized by three distinct phases: the acute phase, when the ischemic 
attack is followed by reperfusion; the sub-acute phase, with the formation of the glial scar (a 
process that requires few weeks); and lastly the chronic phase, which is characterized by the 
continuation of the inflammatory process and neurogenic response. The outcomes of the 
ischemic stroke are visible for the rest of the affected person’s life and often include 
conditions such as diminished motor function of the paretic side, impairment of speech and 
loss of vision, which gravely reduce the quality of life and increase the overall mortality. 
More than 20% of the people that will experience a stroke will be dependent on others for 
assistance; as a consequence health care costs are increased in this category of population. 
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Risk factors for stroke are both modifiable (smoking, high alcohol consumption, physical 
inactivity, unhealthy diet) and non-modifiable (sex and genetic predisposition). Both sex and 
age are important factors, with women below 85 years of age having a lower risk compared 
to men. However after this age limit this trend reverses. Stroke patients often have one or 
more concomitant comorbidities such as diabetes, cardiovascular diseases or kidney disease, 
which further contribute to the poor prognosis of recovery and predispose to higher mortality 
rates than the healthy population. In 2010, the direct and indirect costs of stroke amounted to 
36.5 billion US dollars just in the United States (114). 
After the ischemic event, it is possible to identify two distinct areas: the ischemic core and the 
penumbra. The core is characterized by blood flow below 10-25% (10-12ml/100g/min or 
less) of the normal levels and low ATP levels. This is the area with the highest degree of cell 
death; neurons are the cell type that is the most susceptible, but many of the glial and 
supporting cells are lost as well. The damage within the core is such that even if treatment is 
provided within four hours from the ischemic event and normal blood flow and ATP levels 
are restored, cell death is inevitable. The penumbra, instead, is the area between the necrotic 
core and the unaffected tissue where the lack of oxygen and nutrient is not such to cause 
irreversible damage (60ml/100g/min). Many of the cells in the penumbra may even survive 
and recover after the ischemic event, as long as treatment is provided within few hours. The 
penumbra is also where the endogenous regenerative process takes place in the weeks and 
months following a stroke. 
The main events that lead to cell death during and after an ischemic event are depletion of 
oxygen and glucose. These will cause a drop in the levels of ATP that will result in the 
impairment of many processes necessary for cell survival. Duration, intensity and location of 
the ischemic event are directly correlated with the extent of damage. Within the first minutes 
after the ischemic event, the pre-synaptic voltage dependent Ca2+ channels are activated, 
leading to uncontrolled release of excitatory amino acids that are left in the extracellular 
space. The accumulation of such amino acids creates a toxic environment with uncontrolled 
activation of N-methyl-D-aspartate receptor (NMDA) and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPA) receptors, resulting in the activation of proteases, 
lipases and nucleases that will lead to cell membrane damage and cell death (115).  
All the processes described above are responsible for the immediate damage and cell death by 
necrosis that takes place during the acute phase within the ischemic core. During the later 
phases of stroke, peripheral neurons are exposed to adverse conditions that may lead to 
apoptotic cell death. Genes like Bcl2 and p53 are up-regulated and induce the release of pro-
apoptotic signals like cytochrome c, which speeds up the activation of the Caspase cascade 
(116). Other cell death pathways induced by the ischemic event include p53 (117), Jnk (118) , 
c-Jun, p38 and Cdk-5 (119). 
The ischemic event and the subsequent hypoxia induce the release of proteases in the 
surrounding tissues, which cause disruption of the extracellular matrix. The BBB is also 
impaired, allowing uncontrolled diffusion and secondary damage (reviewed by (120)). 
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Inflammatory processes are also associated with further propagation of the injury and they are 
typical of the chronic phase of the disease. 
As mentioned in this chapter, stroke is a severe disease, but many of the patients that are 
affected will recover to some degree. This is possible because the brain responds to the injury 
by activating a neurogenic response that may be responsible for functional recovery (121), 
but more evidence are needed. In the next part of this chapter I will discuss the characteristics 
of the endogenous regenerative process following stroke and how the scientific community 
has tried to modulate it and enhance it. 
 
3.2.2 Neurogenic response to stroke 
Following the ischemic event, NSCs in the rodent SVZ become activated and increase their 
neurogenic ability (122–124) (process summarized in Figure 4). Injection of BrdU in animals 
following the induction of an ischemic event allowed the identification of cells either BrdU 
and DCX/PSA-NCAM positive or BrdU and NeuN positive (64,123). 
Many of the neuroblasts that are generated as a response to stroke do not migrate through the 
RMS, but detach from it and migrate towards the injured area, both in the cortex and in the 
striatum. In the striatum, neuroblasts start to express markers typical of the striatal medium 
spiny neurons (like Pbx and Meis2 and DARP-32 after complete differentiation) that are the 
most affected cells during stroke (64). NSCs in the SVZ of rodents increase their neurogenic 
potential immediately after stroke, but they stay activated for several months during the 
chronic phase of the disease (125) and neuroblasts are observed to migrate into the lesion site 
for up to one year (126). 
To be able to detach from the RMS and migrate to the penumbra of the ischemic area 
neuroblasts use the vasculature as a scaffold (127), taking advantage of the neo-angiogenic 
process taking place within the injured brain. Within the striatum of rodents following stroke, 
neuroblasts are often observed adjacent to blood vessels and their migration can be modulated 
by infusion of factors able to influence the angiogenic activity (124,125,128). Moreover, The 
Slit-Robo signaling is used by neuroblasts to migrate through the glial scar and by 
manipulating it is possible to allow further migration into the injured area (129).  
Detachment of neuroblasts from the RMS and migration into the ischemic area is also 
regulated by the release of metalloproteases, chemokines and chemokine receptors (like 
CXCR4) (125,128,130–133), which I previously mentioned as factors released in the area of 
the brain that experiences an ischemic event. The detachment of the neuroblasts from the 
SVZ and their migration towards the striatum comes at the expenses of neurogenesis in the 
OB. After stroke, less neurons will be formed in the OB located on the same hemisphere as 




The approaches of foremost interest are the ones based on the use of stem or progenitor cells 
and they can be divided in two main categories: transplantation from exogenous sources or 
stimulation of the endogenous population. 
 
3.3.1 Transplantation from exogenous sources 
3.3.1.1 Human fetal NSCs 
The stimulation of the endogenous stem cell niches presents some intrinsic limitation. As 
mentioned previously, the NSCs in the adult mammalian brain are less active and more 
difficult to stimulate. That is why many groups are addressing the concept of using cells from 
exogenous sources. This way it is possible to have active stem or progenitor cells and to 
transplant them in high numbers. The role of the transplanted cells would be both to replace 
the dead cells and to provide support and thus create a pro-regenerative environment, for 
example by secreting pro-neurogenic factors. 
Transplantation protocols have been attempted with fetal stem cells, embryonic stem (ES) 
cells and induced pluripotent stem (iPS) cells (Figure 5). Similar approaches have already 
been tested in humans with positive results for treatment of PD (for extensive reviews see 
(138,139)), giving hope for similar outcomes in patients with stroke. The most promising 
studies are the ones where human cells have been tested for their capacity to generate neurons 
after transplantation into the brain of rodents following stroke. Many of these attempts have 
been based on human fetal stem cells (140–143) but also on iPS cells (144).  
Human fetal stem cells transplanted into the brain of rodents following induction of stroke 
were able to migrate into the lesion site and differentiate into neurons both in the striatum 
(141) and in the cortex (143). The studies in the cortex also revealed that transplantation 
outside the ischemic area greatly improves survival of the transplanted cells. Moreover, 
brains in which the immune response was stronger were less favorable for the survival of the 
transplanted cells (143), but fetal NSCs grafted into the stroked rodent brain have been 
reported to decrease the levels of inflammatory molecules (145). The transplanted cells were 
able to mimic the traditional differentiation process: after transplantation, they would start to 
express neuroblast markers like Dcx and migrate towards the lesion site, where they would 
lose the migratory phenotype and differentiate into immature neurons (recognized by their 
expression of βIII-tubulin). These cells are not only able to generate new neurons, but they 
also secrete factors such as VEGF that can improve the regenerative environment in the brain 
(142). The transplantation of fetal human stem cells also improved the connectivity and 
dendritic plasticity in the uninjured hemisphere (140). Moreover, pre-differentiation into 
GABAergic neurons before transplantation was reported to improve the recovery after stroke 
(146). 
One of the goals of the studies mentioned above was also to test whether human fetal stem 
cells isolated from different regions harbor a different regenerative potential once 
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transplanted in different brain regions. NSCs isolated from the fetal cortex or striatum are 
both able to survive and migrate through the injured striatum of rodents after transplantation. 
This further supports the idea that the striatum is an area permissive for neurogenesis and the 
environment plays an important role in the regenerative capacity of stem cells. Nevertheless, 
NSCs isolated from the striatum were able to migrate further than their cortical counterpart, 
allowing for the regeneration of bigger portions of tissue (141). It is interesting to speculate 
whether this ability is intrinsic to striatal NSCs or if it is simply because they are in an 
environment that was more similar to the one they have been isolated from. 
The ideal timing and number of cells for transplantation have also been investigated (147). 
Cells transplanted 48 hours after the induction of the ischemic event survive better than cells 
transplanted 6 weeks after the stroke. This observation may be explained by the fact that at 
later time points the glial scar is completely formed and the inflammatory cells migrated in 
the area create a stabilized environment rather than one prone to regeneration where most of 
the damaged tissue is irremediably impaired. What’s more, the same study also showed that 
increasing the number of transplanted cells does not improve the regenerative process. 
Similar studies have been repeated in monkeys, an animal model closer to humans (148). 
Human fetal NSCs survived in the monkey brain for the entire length of the study (105 
days) when transplanted 1 week after the ischemic event. The transplanted cells also started 
to express βIII-tubulin, a marker for immature neurons. 
All the studies presented until here are based on intracranial transplantation of the stem 
cells, but systemic delivery approaches have also been tested in the past. Transplantation of 
human fetal NSCs in the brains of rats 24h after stroke induced an improvement in the 
behavioral recovery of the animals (149). Survival and differentiation of the transplanted 
cells was assessed up to 540 days after transplantation, but they were also observed in other 
tissues (kidneys, lungs and spleen). The improvement in these animals does not seem to be 
induced by the formation of new neurons, but rather by white matter recovery and release 
of neurotrophic factors, as speculated in similar studies (150–152). Another mechanism that 
improves recovery following transplantation is the up-regulation of the glutamate 
transporter Glt-1 in astrocytes (153). 
Transplanted human fetal NSCs have also been observed to improve endogenous 
neurogenesis (154). In this study, fetal cells were transplanted 48h following stroke and 1 to 
2 weeks after transplantation it was possible to observe graft-derived neuroblasts. SVZ-
derived neurogenesis was also improved in these animals and they all performed better at 
several behavioral tests. 
Optimizations of the protocols have been applied to increase cell survival, migration, 
differentiation and overall recovery. It is possible to improve the survival of fetal-derived 
NSCs by pretreatment with Tnf-α (155), overexpression of Cu/Zn-Superoxide dismutase 
(156) and Il-6 (157). 
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Human fetal NSCs have been used in a phase 1 clinical trial in patients affected by stroke 
(158). In this study it was observed that transplanted cells were able to produce factors 
responsible for inducing angiogenesis, neurogenesis and suppressing inflammation. No 
adverse effects were observed in the eleven patients involved in the study. Moreover, 
neurological improvements were visible already one month after transplantation and were 
stable for up to two years later. A second clinical trial followed in patients with motor 
dysfunction of the upper limb consecutive to a stroke (159). Patients were transplanted with 
20 million human fetal NSCs and, at one year from transplantation, no adverse effect was 
observed. Improvements in different clinical parameters were observed in fifteen patients out 
of twenty-three. 
 
3.3.1.2 Embryonic stem cells 
ES cells have also been transplanted in the rodent brain following stroke. These cells were 
able to migrate towards the injured area and induce behavioral improvement (160). The 
transplanted ES cells are also very efficient at differentiating into mature functional neurons 
and it has been estimated that around 30% of the transplanted cells become positive for 
neuronal markers (161,162). The neurons generated by human ES cells in the brain of rodents 
following stroke are also able to develop axonal projections that extend for long distances, 
similar to the ones observed in the uninjured rodent brain (163). Cells implanted in the motor 
cortex developed axons into the cervical spinal cord and into the cortex of the contralateral 
hemisphere. Pre-treatment of ES cells with BDNF was reported to improve cell survival and 
functional recovery in ischemic mice (164). 
The advantage of human ES cells is that they can generate a virtually unlimited number of 
NSCs and can be directed into any neuronal subtype. However, this also represents the 
biggest drawback of this system. Unlike human fetal stem cells, tumor derived from the 
transplanted ES cells have been observed (165). The most recent studies on human ES cells 
are introducing steps of pre-differentiation to limit the tumorigenic potential of the 
transplanted cells, which seems to be a successful strategy. Nevertheless, more studies are 
needed to better characterize this phenomenon. 
 
3.3.1.3 Induced pluripotent stem cells 
As ES cells, iPS cells are able to differentiate into specific neuronal subtypes. Another 
advantage of using iPS cells is that they can be generated from cells isolated directly from the 
patient, avoiding any compatibility and rejection outcomes or ethical issues (166). 
Human iPS cells transplanted into the brain of rats following stroke have the ability to 
migrate into the ischemic area and participate to the recovery processes already 4 to 16 days 
after transplantation (167). These results need to be considered carefully, as a separate study 
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failed to assess any improvement, although survival of the transplanted cells and neuronal 
differentiation was verified (168,169). Observations in these studies were limited, since many 
important aspects such as formation of tumors and differentiation into neuronal subtypes 
were not properly addressed. The tumorigenic potential of iPS cells has been proven when 
undifferentiated cells have been used for transplantation (169,170). Moreover, the ischemic 
environment in the brain seems to induce a stronger tumorigenic potential compared to the 
healthy brain (169). Survival and differentiation into mature and functional neurons were 
later shown in another study (144). In this case, fibroblast-derived iPS cells were transplanted 
into the striatum of rats following stroke. The iPS-derived neurons were forming axonal 
projections directed towards the globus pallidus. Motor recovery improvement was also 
observed following transplantation. As seen in the other studies, the improvement in behavior 
was rapid (1 week), suggesting mechanisms that are independent of the formation of new 
neurons. 
Subsequent studies developed new systems to obtain iPS cells from blood derived monocytes 
(171–173), in particular, the use of non-viral systems is able avoid the integration of viral 
sequences in the genome. iPS cells derived through non-viral methods and differentiated into 
NSCs have been transplanted in the rodent brain following stroke, with successful recovery 
(174). Good results have also been obtained by transplanting human iPS-derived NSCs in the 
brain of mice and rats that experienced an ischemic event (175–178). 
The mechanism by which iPS cells induce recovery after stroke is still to be clarified: iPS-
derived neurons develop functional synapses and integrate into the pre-existing neuronal 
circuit (175,176), but other studies suggest that the main support provided by the transplanted 
cells is via secretion of trophic factors, modulation of inflammation, support of the surviving 
tissue and reduction of brain atrophy (177,179–182). Improvement of recovery following 
transplantation of iPS-derived cells in the ischemic rodent brain have been observed even in 
aged animals (183). 
No clinical trial is ongoing at the moment with iPS cells for the treatment of ischemic stroke. 





3.3.2 Stimulation of endogenous neurogenesis 
Endogenous neurogenesis following stroke is often not sufficient to guarantee a full recovery. 
Many steps of the neurogenic process could be targeted to increase the regenerative ability of 
the brain including: NSCs proliferation, differentiation in neuroblasts, cell migration and 
survival, maturation into neurons and integration into the pre-existing neuronal circuits. 
Molecules like Vegf have been involved in the process of neurogenesis and it is now known 
that they are necessary for NSCs activity (194). Injection of the Neuropeptide Y into the LV 
stimulates NSCs to proliferate and migrate both in the OB and in the striatum (195). 
Similarly, Egf is a potent mitogen for NSCs and if infused in the LV induces a migratory 
phenotype (10,34), while erythropoietin has been reported to induce neuronal differentiation 
(196). Studies based in the injection of Egf and erythropoietin in the rodent cortex following 
stroke have shown an increase in the regenerative capacity of the tissue and recovery of 
motor functions (197). Both the stromal cell-derived factor 1α and the monocyte 
chemoattractant protein 1 have been involved in cell migration after stroke (130,131). 
Neuronal survival has been successfully improved after stroke by administration of anti-
inflammatory and anti-apoptotic molecules (198–200). 
Forced expression of Ascl1 has the ability to induce reactive astrocytes differentiation into 
neurons in the mouse cortex following stroke (201). This could be used with the double goal 
to reduce gliogenesis and enhance neurogenesis. 
To be able to move these strategies from the bench to the clinic, the connection between 
increased neurogenesis and functional recovery needs to be proven. Moreover, direction of 
migration towards the lesion site may be more problematic, considering that the distance that 
has to be covered in the human brain is greater than what can be modeled in the rodent brain. 
All the approaches presented above have some intrinsic limitations. For endogenous 
neurogenesis the weak response to injury, the limited number of cells that can be generated 
by the adult NSCs and the distance these cells would have to migrate restrain their usage. As 
for the transplantation techniques, the potential rejection of the transplanted cells along with 
the ethical problems and the tumorigenicity has a negative impact on their adoption for 






Astrocytes are one of the most common cells in the mammalian brain and they are distributed 
in every part of it (202). They share expression markers (9,203) and electrophysiological 
profile (204) with stem cells and have been observed to be prone to acquire stem cell 
properties in different conditions (the topic will be discussed later in this chapter). Because of 
these peculiar characteristics they attracted our attention as a source of new neurons. If 
astrocytes could be used to regenerate portions of damaged tissue, many of the limitations 
listed in chapter 3 would be overcome. Astrocytes could be a source of new neuronal cells 
that can be stimulated from within the brain and that does not have to migrate, since 
stimulation could occur locally in the damaged area. 
 
4.1 CHARACTERISTICS AND FUNCTIONS OF ASTROCYTES 
The name astrocyte comes from the description of their star-shaped morphology as described 
using the Golgi staining and Gfap immunolabeling. Although this basic description is not 
wrong it gives an incomplete idea of their morphological appearance. Astrocytes are 
characterized by the presence of numerous fine processes that are negative for Gfap, which is 
now known to be visible in approximately 15% of the entire astrocyte volume (205). They are 
often observed in close proximity to, and interacting with, blood vessels and neurons. Several 
markers are used to identify astrocytes, even though none of them can be considered specific, 
ubiquitous or restricted to astrocytes or labels all astrocytes sub-types, between them the ones 
worth of mention are: Gfap, S100β, aldehyde dehydrogenase 1 family member L1 (Aldh1L1) 
and Connexin 30 (Cx30). Astrocytes exhibit high heterogeneity in aspects, such as 
developmental lineage, mitotic control, receptors and ion channel expression, gap junction 
connectivity, electrophysiological and calcium signaling properties (206). 
An in-depth analysis of astrocyte subtypes revealed nine different kinds of astrocytes and 
their distribution within the mouse brain (207). A more recent study that aimed at 
characterizing the molecular architecture of the nervous system estimated astrocytes to 
compose between 6 to 13% of all cells, depending on the region considered (208). In this 
study, seven distinct subtypes of astrocytes with regionally specialized distribution have been 
identified. Studies of the interaction between astrocytes domains showed how there is little to 
no interaction between them and that in the hippocampus and cortex they tend to organize in 
districts (205,209–212). 
Regarding the functions of astrocytes, they are involved in many different processes in both 
the healthy and the pathological brain. Astrocytes are involved in the maintenance of brain 
homeostasis, support to neurons, transport and recycling of glutamate and other 
neurotransmitters, and the formation of the BBB and modulation of synapses plasticity 
(205,213–220). One of their major functions is glutamate uptake. Astrocytes express proteins 
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involved in glutamate transport like GLAST and GLT-1. Neurons release the glutamate in the 
synaptic space and astrocytes uptake it to control the signal transmission between neurons. At 
the same time, astrocytes are of support to neurons by providing glutamine, so that the 
glutamate storage in the presynaptic neuron is never depleted. 
 Astrocytes employ a variety of gliotransmitters to communicate with nearby cells. Studies in 
vitro revealed that Glutamate, ATP, adenosine, d-serine, Tnf-α and eicosanoids are released 
following increase of intracellular calcium levels (221–225). Nevertheless, the astrocytes’ 
ability to release gliotransmitters to activate neurons has to be proven in vivo in physiological 
conditions.  
Astrocytes are also involved in the formation of the glial scar following injury and more 
about it will be discussed in the following paragraph.  
Astrocytes are involved in the regulation of neurogenesis in the niches and they are present in 
great numbers both in the SVZ and in the DG. Expression of IL-1, IGFBP6, decorin and 
encephalin inhibits NSCs differentiation, while IL-1β and IL-6 promote it (226,227). 
Astrocytes also express thrombonspondin 1 to induce NSCs proliferation (228). In the DG 
astrocytes are able to promote NSCs proliferation and differentiation by providing Wnt (229), 
EphrinB2 (230). In the SVZ, niche astrocytes express Wnt7a and Bmp ligands to promote 
neurogenesis (25,231). Moreover, SVZ astrocytes express Notch ligands, like Dlk1 (232), 
that can bind Notch receptor on the membrane of NSCs and allow the modulation of 
neurogenesis (233). Astrocytes in which nestin has been knocked-out are unable to induce 
activation of Notch signaling in NSCs, resulting in increased neurogenesis (234).  
 
4.2 ASTROCYTES IN STROKE 
Astrocytes have an important role following ischemic stroke, they are able to respond rapidly 
by expressing different genes, the most important being involved in STAT signaling 
(235,236), and become reactive. During this process, astrocytes up-regulate GFAP, vimentin 
and nestin, the number of their processes is reduced and they become thicker and astrocytes 
themselves start to proliferate (237–239). Within 24h after stroke in the mouse brain, very 
few astrocytes are positive for the proliferation marker Ki67, but this changes 3 and 5 days 
after injury, when the percentage of proliferating astrocytes increases to 17 and 29% 
respectively (240). During the acute and sub-acute phase of stroke, astrocytes within the 
penumbra participate in the formation of the glial scar, which is a physical barrier that stops 
infiltration of immune cells in the healthy tissue (241,242). Although the glial scar has an 
important role in the survival of the tissue and recovery during the first phases after injury, as 
observed in mice knockout for GFAP and vimentin (243), it later represents a limiting factor 
for the regenerative process (244). A transcriptome study of reactive astrocytes revealed that 
they are able to respond differently depending on the stimulus (245). In particular, although 
both stroke and LPS injection induce gene expression, reactive astrocytes in stroke express 
more genes than after LPS injection. 
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Another role of astrocytes in stroke is to avoid the formation of brain edema. Astrocytes 
respond to the formation of a hypo-osmotic environment in the brain by releasing osmotically 
active molecules (246–248), which will cause cellular swelling. 
Reactive astrocytes may also negatively affect neurons following brain ischemia. In the 
ischemic cortex, up-regulation of Ephrin-A5 may inhibit axonal sprouting and recovery 
(249). Moreover, impaired functions of GABA transporter Gat-3/Gat-4 may inhibit 
synaptic plasticity following stroke (250). 
Modern techniques, like single-cell transcriptomics analysis, are allowing us to further 
characterize cells, both in the healthy and diseased brain. Using these methods, a 
subpopulation of cells that expresses both astrocyte- and microglia-specific genes has been 
identified (251). These cells are found in the hippocampus of mice following injury and in 
the brains of individuals that suffered a stroke or are afflicted by AD, but not in the healthy 
brain of either species. 
Another feature of astrocytes following stroke, and the most interesting one in regards to 
this thesis, is their ability to become neurogenic. More about it will be discussed during the 
rest of this chapter.  
 
4.3 ASTROCYTE-DERIVED NEUROGENESIS 
In this thesis, the main interest in astrocytes is their ability to generate new neurons, either 
spontaneously in injury models (8,9) or after manipulation by researchers (4–
6,9,201,252,253). 
Astrocytes are very similar to NSCs in many aspects, including: marker expression (203), 
electron microscopy features (254,255), electrophysiological profile (204) and gene 
expression (256), leaving scientists to wonder whether it would be possible to induce a 
neurogenic program in astrocytes. By forcing the expression of transcription factors 
associated with neuronal differentiation it was observed that astrocytes are able to generate 
new neurons. Transfection to force Neurog2 expression in cortical astrocytes induced direct 
differentiation into glutamatergic neurons, while Dlx2 determines a GABAergic neuronal 
identity (4). In the same study it was also proven that isolation of the cortical astrocytes and 
cultivation in neurospheres increased the efficiency of the reprogramming protocol, 
suggesting a role of the cortical environment in suppressing the potential of astrocytes to 
generate new neurons. Moreover, neurospheres derived from cortical astrocytes were not able 
to generate neurons if isolated from the uninjured cortex, while they were able to do so when 
isolated from the mouse cortex after stab wound injury. 
To understand what may influence the neurogenic potential of astrocytes in vivo we have to 
also keep in mind the role that the environment plays in neurogenesis. Experiments of ectopic 
transplantation have proven that cells isolated from the hippocampus, spinal cord and 
substantia nigra can be transplanted in the DG and generate neurons locally (257–259). When 
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such studies have been repeated in the striatum the results have highlighted that this region 
may not be as beneficial for the generation of new neurons, compared to the hippocampus 
(24,260,261). A following study even reported no signs of neurogenesis after transplantation 
of SVZ derived cells (262). However, when ES cells were used as source material for 
transplantation, both the striatum and the cortex were able to sustain formation of new 
neurons (263,264). Results from these studies suggest that, even though there are cell 
intrinsic neurogenic properties, the environment can be either a limiting or an enhancing 
factor to the manifestation of the neurogenic potential. 
By inducing the expression of NeuroD1, researchers were able to convert astrocytes into 
neurons both in vitro and in vivo (4,5). Similar results were obtained with Sox2 and Ascl1 
(6,7). Conversion of mouse astrocytes was also obtained by expression of Foxg1, Sox2 and 
Brn2 (265) and the neuronal subtype specification was modulated by overexpression of 
specific genes like Lhx8 (cholinergic neurons) and Foxa2 (dopaminergic neurons). Small 
molecules have also been used for the differentiation of astrocytes into neurons: valproic 
acid, Chir99021 and Repsox (266). 
Independently of external manipulation by scientists, astrocytes have been observed to have 
an intrinsic potential to generate neurons. The induction of ischemic stroke in the brain of 
adult mice triggers a latent neurogenic program in astrocytes (9). In this model, astrocytes 
revert to a transit-amplifying progenitor state, characterized by the expression of Ascl1, and 
undergo several cycles of cell division before differentiation into Dcx-expressing neuroblasts 
and finally into neurons. In the same study it was proven that this process is dependent on the 
down-regulation of Notch signaling and the knockout of Rbpj induces astrocyte-derived 
neurogenesis even in the absence of injury. Unlike in the stroke model, astrocytes in the 
brains of Rbpj-/- mice generate neuroblasts only in proximity of the SVZ, suggesting that the 
proximity of the niche supplements for the pro-neurogenic stimuli missing in the healthy 
brain. A study published soon after also identified striatal astrocytes as a source of new 
neurons in an injury model based on the injection of quinolinic acid (8). While the 
reprograming studies mentioned above are based on a direct conversion from astrocyte to 
neuron, in these studies astrocytes generate new neurons following similar steps to the NSCs, 
adding another layer of similarities to the one listed at the beginning of this paragraph. This 
further implies that, if by transdifferentiation it is possible to have a one-to-one conversion 
rate, by stimulating the endogenous potential of astrocytes each cell could generate several 




Figure 6: Astrocyte-derived neurogenesis in the mouse striatum. Mature astrocytes in the mouse striatum can 
become neurogenic following stroke or by blocking Notch signaling. When the neurogenic program is induced, 
astrocytes lose their typical morphology and become round. At this point they start to express markers typical of 
transient-amplifying progenitor cells and proliferate, forming clusters. These clusters of Ascl1 positive cells will 
further mature into Dcx-expressing neuroblasts, which will then separate from each other and mature into 
neurons. (Image Magnusson JP, Frisén J. Stars from the darkest night: unlocking the neurogenic potential of 
astrocytes in different brain regions. Development. 2016;143(7):1075-1086. doi:10.1242/dev.133975. Used 
with permission from The Company of Biologists) 
 
The neurogenic potential of astrocytes has been observed not only in the striatum, but also in 
the cortex. Following stab wound injury, astrocytes are able to proliferate and self renew and, 
if isolated, show multipotency (267). Other studies proved that the overexpression of Ascl1 in 
SVZ-derived reactive astrocytes in the cortex following stroke has the ability to 
transdifferentiate these cells into neurons (201). Similar results in the cortex have been 
obtained reprogramming both reactive and quiescent astrocytes by overexpressing Ngn2 and 
Nurr1 (268). Moreover, Notch signaling importance has also been shown in the cortex where, 
by inducing an injury in Rbpj knockout mice, it is possible to trigger astrocyte-derived 
neurogenesis (269). In this last study, it was shown once again that the injury-induced 
neurogenic program in astrocytes closely resemble the one from SVZ NSCs when single-cell 
RNA sequencing is performed (256,269). 
Human astrocytes have also been reprogrammed into neurons using different protocols, 
proving their potential for future therapies. The simultaneous inhibition of Notch, BMP, 
GSK-3β and TGFβ signaling using small molecules converts human fetal astrocytes to 
neurons in vitro and mouse astrocytes in vivo (270). Human astrocytes in which NEUROD1, 
ASCL1, LMX1A and NR4A2 were overexpressed successfully differentiate in dopamine 
neurons and mouse astrocytes converted in the same fashion can be used to recover the 
phenotype in a mouse model of PD (271). Similarly to overexpression of transcription 
factors, small molecules can induce adult human astrocytes to differentiate into neurons 
(272). In this study, researchers used valproic acid, Chir99021 and Repsox (already efficient 
in converting mouse astrocytes (266)) in combination with forskolin, i-Bet151 and ISX-9 to 
differentiate astrocytes into neurons. Although it is suggested in this study that differentiation 
of astrocytes using this protocol avoids conversion into progenitor cells, Ascl1- and DCX-
expressing cells have been observed. This suggests that the conditions mentioned in the study 
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trigger astrocyte differentiation into transient-amplifying progenitor cells, rather than direct 
transdifferentiation into neurons, as observed in other studies (9,269,273). Other cocktails of 
small molecules have proven efficient in differentiating human astrocytes into neurons (274), 
opening the possibility to use this strategy in the clinic and avoiding the use of viruses for 
overexpression of transcription factors. 
Astrocytes are now considered a promising source of new neurons within the adult 
mammalian brain and in the rest of this thesis I will show how our most recent work can 





5 PRESENT INVESTIGATION 
 
5.1 AIMS 
Paper I – Understand if previous models aimed at inducing astrocyte-derived neurogenesis 
can synergize and stimulate astrocytes in non-neurogenic regions to produce neurons. 
Paper II – Generate two single-cell RNA sequencing datasets to elucidate the mechanisms 
behind astrocyte-derived neurogenesis. Use the dataset to compare neurogenic and non-
neurogenic astrocytes. Identify and validate signaling pathway with a potential to induce 
astrocyte to become neurogenic. 
 
5.2 PAPER I – RESULTS AND DISCUSSION 
The results previously generated by our lab, prompted us to wonder if stroke and deletion of 
Notch signaling can have a synergistic effect on neurogenic astrocytes. Moreover, we wanted 
to test if, by combining the two conditions, we could induce neurogenesis in the lateral 
striatum, which is not neurogenic in mice knockout for Rbpj. 
To test our hypothesis, we deleted Rbpj specifically in astrocytes, by giving tamoxifen to 
mice that express CreER under the control of the astrocyte promoter Connexin30 (Cx30) in 
which the gene encoding for Rbpj is flanked by FloxP sequences. CreER translocation into 
the nucleus of astrocytes induces also expression of the reporter Tomato. One week after 
tamoxifen injection, we induced a stroke by using the Middle Cerebral Artery Occlusion 
model (MCAO). Animals were sacrificed 7 weeks after stroke and the ischemic hemisphere 
was compared with the uninjured one and with the ischemic hemisphere from wild-type 
mice. 
We observed an increase in the number of neuroblasts and transit-amplifying progenitor cells 
in the stroke-injured hemisphere when compared both to the uninjured side and to the 
ischemic hemisphere of wild-type mice. Neurogenic cells differentiate into mature neurons, 
as assessed by the presence of Tomato-positive mature neurons (identified by the expression 
of the marker NeuN), although the number of astrocyte-derived neurons is not significantly 
higher than in the uninjured side. This lack of difference may be explained by the early time-
point for analysis or by the fact that additional neurons are not integrated into the pre-existing 
neuronal circuits and die. 
Two hypotheses may explain the increase in neurogenic cells: astrocytes that entered the 
neurogenic program due to deletion of Rbpj were stimulated by stroke to proliferate more or 
more astrocytes became neurogenic. To answer this question, we quantified the number of 
cell clusters. We previously described how each cluster is generated by one neurogenic 
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astrocyte and further proofs are presented in the supplementary figures of this paper. We 
observed a significant increase in the number of clusters of transit-amplifying progenitor 
cells, suggesting that more astrocytes became neurogenic. The position of many of these 
cells, in very lateral areas of the striatum, where usually they are not observed, further 
supports this idea. Neuroblast clusters do not seem to be affected, but this may be explained 
by the migratory nature of neuroblasts, which clusters may dissolve to allow cells to migrate 
to the site of injury. 
Taken together, the data gathered in Paper I suggests that many, if not all, striatal astrocytes 
maintain a neurogenic potential. Notch signaling has an important role in maintaining 
astrocytes quiescent, but further stimuli are needed to initiate a neurogenic program. 
 
5.3 PAPER II – RESULTS AND DISCUSSION 
The results from our previous publication (9) and from Paper I suggest that astrocytes’ 
ability to generate neurons is regulated by Notch signaling, which acts as a brake on cell 
proliferation and differentiation, but further stimulation can enhance the neurogenic program. 
Also, similarities to SVZ neurogenesis emerged, however it was still unclear to which extent 
the two processes are similar. To further investigate these two points, we decided to perform 
single-cell RNA sequencing on astrocytes from Rbpj deleted animals. 
In particular, we decided to employ two different sequencing techniques: Smart-seq2 and 
10X Genomics sequencing. The first method was used to sequence astrocytes from Rbpj 
deleted animals treated with tamoxifen, so the derived dataset is called Cx30-CreER dataset. 
The second dataset was instead derived from astrocytes isolated from the brain of mice 
injected with a Cre-expressing Adeno Associated Virus (AAV), hence the name AAV-Cre 
dataset. This second dataset was also used to prove that there was no contamination from 
SVZ derived cells in our data. 
Comparisons of our two datasets with previously generated ones revealed that striatal 
astrocyte-derived neurogenesis follows steps more similar to SVZ derived neurogenesis 
rather than DG-derived neurogenesis (256,275,276). Striatal astrocytes appear to be a form of 
quiescent stem cells that when activated differentiate into transient-amplifying progenitor 
cells and later in neuroblasts. 
Nevertheless, the majority of astrocytes in the striatum and in the cortex (a non-neurogenic 
area in our model) appear to activate the neurogenic program following Rbpj deletion, but get 
halted in a pre-division phase and do not generate neuroblasts. To test if administration of 
external stimuli could trigger these halted astrocytes to commit to differentiation, we screened 
for the expression of growth factor receptors involved in NSCs differentiation. Egf receptor 
was highly up-regulated in these astrocytes and administration of Egf in the lateral striatum 
triggered a two-fold increase in the number of neuroblasts. Nevertheless, injection of Egf in 
the cortex was not sufficient to increase astrocyte-derived neurogenesis. 
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In conclusion, the data from Paper II show that striatal astrocytes follow a neurogenic 
trajectory reminiscent of the NSCs from the SVZ. Thus, astrocytes can be considered a form 
of stem cells in which the default state is quiescence. By blocking the Notch signaling it is 
possible to reactivate the neurogenic potential of astrocytes, which become receptive to 
environmental stimuli like Egf. In other areas of the brain like the cortex, the process is 
similar, but stronger stimuli are needed and this has been further addressed by our group in 




6 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
This thesis aims at giving an overview of regenerative medicine of the brain, its application to 
stroke, the use of astrocytes to generate new neurons and how my work has been relevant to 
the subject. 
The goal of regenerative medicine is to increase the healing ability of the adult human body 
and potentially step beyond its natural limits. In particular, the aim is to completely recover 
the functionality of injured tissues and organs. The application of regenerative medicine to 
the brain attracted interest in the past decades because the complexity of the tissue and its 
structure makes it particularly vulnerable to injury. Stroke represents one of the most 
common kinds of injury in the human brain and with substantial repercussions both on the 
lives of afflicted people and overall on the society. The main strategies that have been 
adopted until now to overcome the neuronal death induced by an ischemic event rely on the 
use of stem cells and have been listed in chapter 3. There are two main approaches: the 
stimulation of endogenous neural stem cells and the transplantation of progenitor cells from 
exogenous sources. Although discoveries and therapeutics attempts have been carried out 
following both lines of research with good results, some limitations emerged that are 
prompting the scientific community to look for alternative solutions. Transplantation of 
progenitor cells from exogenous sources proved efficient in providing sources of new 
neurons in the damaged area of animal models. Nevertheless, fetal and ES cells could be 
problematic from an ethical point of view and the availability of donor cells. Not only is it 
difficult to obtain donor cells for these particular approaches, but even when tissue is 
available, the isolation of enough cells is laborious and problematic. The use of iPS cells has 
been promising to avoid these limitations, but these cells require extra differentiation steps to 
reduce the possibility to generate tumors. Stimulation of endogenous neurogenesis on the 
other hand can be difficult because in the adult human brain the stem cells are not as 
numerous and active as in the developing brain or in the animal models that are currently in 
use. Moreover, the ability of eventual immature neurons to migrate efficiently over long 
distances is not confirmed and may represent a considerable limitation. These issues 
prompted the search for a source of new neurons that could overcome the ethical discussion, 
the problem of having enough cells, tumorigenicity and require as little and invasive surgeries 
as possible. Astrocytes have been one of the answers and they seem to be able to bypass most 
of the above-mentioned limitations. 
Several studies addressed the ability of astrocytes to generate neurons and these have been 
summarized in chapter 4. The two papers presented in this thesis aim at contributing to the 
knowledge of how striatal astrocytes may have an intrinsic neurogenic ability but, unlike 
neural stem cells, they are intrinsically quiescent because of Notch signaling. The deletion of 
Rbpj in astrocytes impairs Notch signaling triggering the cell to initiate a pro-neurogenic 
response. Yet, this is not enough to induce neurogenesis, but a first step to exit the quiescent 
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default state. More signals need to be provided such as the ones released after an ischemic 
event in the mouse brain. In the healthy brain, this signals are present nearby the 
subventricular zone, where Rbpj deletion is sufficient to trigger the differentiation into 
neuroblasts and neurons. The neurogenic process in astrocytes resembles the one from stem 
cells in the subventricular zone. Moreover, stroke alone is able to induce astrocyte-derived 
neurogenesis, but the concomitant deletion of Notch signaling allows more astrocytes to 
actively participate in this process. More importantly, stroke is able to activate neurogenic 
astrocytes even in the lateral parts of the striatum, where no neurogenesis is observed even 
when Rbpj is deleted. A similar effect can be induced by the injection of Egf, which receptor 
is up-regulated by astrocytes following Rbpj deletion. Cortical astrocytes behave in a similar 
manner, even if the injection of Egf is not sufficient to induce neurogenesis. Moreover, other 
studies in the literature showed that the induction of an injury can trigger the neurogenic 
program in the Rbpj deleted cortical astrocytes (269). These data suggests that the 
environment around astrocytes is also responsible for the expression of their neurogenic 
potential. 
The future of astrocyte-derived neurogenesis relies on the identification of the pathways that 
are important to regulate this process and which stimuli are needed to induce neuronal 
differentiation. It will be important to verify if the astrocyte-derived neurons can compare to 
the stem cell-derived one. Moreover, these observations are still limited to animal models and 
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